
ABOUT INSEPTION GROUP
inSeption was built on the foundational principle that quality outsourcing solutions must consist of the RIGHT people. Our collective passion to bring treatments and an improved quality of life to patients, unifies us in our mission to change the outsourcing paradigm.
inSeption distinguishes people as the most impactful variable in the outsourcing equation. Our path-breaking model attracts biopharma companies who demand a partner that shares in their drive to conduct impeccable development and will provide quality and dependable clinical solutions. We offer full outsourcing, consulting services, and functional service provider (FSP) solutions for the following services:
CONTACT INFORMATION
inSeption Group
870 W Main Street
Lansdale, PA 19446
UNITED STATES
Phone: (267) 498-5092
FEATURED ARTICLES
- Site-Relationship Strategy: Ensuring Quality Data And Study Performance
- Gap Analysis: Objective Review Benefits Biopharma Clinical Quality Systems
- Case Study: Medical Writing — NDA Submission
- Leveraging Clinical Trial Data In Real Time To Effect Change And Mitigate Risk
- Case Study: Recovering A Clinical Trial That Has Been Derailed
- What Big CROs Don’t Want You To Know About Staffing Scalability For Phase III Studies
- Is A Multitherapeutic Contract Research Partner The Best Fit For Your Clinical Trial?
- Identifying The Best People To Run A Clinical Study (And How To Hire Them)
- Do Small Outsourcing Partners Benefit Small And Emerging Biotechs?
- Keys To Successful Risk Management In Clinical Trials
VIDEOS
-
Everything we do is driven to challenge the status quo in the current outsourcing paradigm. inSeption is a home for clients and professionals who have been stifled by mainstream, high-volume, commoditized outsourcing models.
MYTHBUSTERS
-
09/20/21 Life Science Leader Newsletter
-
Large CROs have a vast pool of resources and a subset of amazingly talented people. However, the decision to select such a CRO on the concept that they have access to the best talent, and the hope that those resources will be assigned to your study, is flawed.
-
Most quantitative and qualitative studies seeking to understand what creates fear and anxiety in humans conclude with some version of the same 4 key criteria: Lack of Control, Large Consequence, Sudden Occurrence, and Unfamiliarity. In our outsourcing industry, it is never an easy decision to select a partner when trying to run complex sequential trials. The need to gain regulatory approval for the treatments you have dedicated yourself to providing, coupled with the need to find a capable, reliable, and fair Contract Research Organization is quite daunting.
-
Chief medical officers looking for outsourcing services on a study are often fed lines from large CROs on how they can provide individuals with multitherapeutic backgrounds.
-
The theory of Corporate Memory is easy to understand and agree with – the better you record and understand recurring actions the better you will perform those actions. Read why Capitalizing on corporate memory might work at an individual level but is nothing more than a myth and an empty promise in the complex changing world of drug clinical studies.
-
Have you ever asked yourself why you take comfort with governance agreements? They're created to "protect" you when your CRO fails - and even then, what can you realistically do? Find out the answers here.
E-BOOKS
-
Discover how clinical research services must wade through a bog of incomplete information, and sometimes outright misinformation, when it comes to seeking reliable partnerships.
-
Biopharma companies — particularly smaller or emerging organizations — often are unable to draw maximum value from CROs. This occurs for any number of reasons, several of which are covered in this e-book.